Get In Touch
Have any questions or comments about the content you see on this page?
Our News
December 21, 2021
As part of our ongoing efforts to ensure that our innovative therapies can be accessed by patients who may benefit them, which is guided by Alnylam's Patient Access Philosophy, and commitment to transparency, we're proud to publish Alnylam's 2021 Patient Access Philosophy report.
The 2021 report summarizes Alnylam’s latest collaborations with payer, provider, regulatory, distributor, and advocacy partners. Importantly, the report demonstrates Alnylam’s steadfast commitment to innovative access initiatives as the company serves more patients and enters new geographies, which is instrumental to its P5x25 strategic plan focused on patients, products, pipeline, performance, and profitability. This year’s report also highlights how Alnylam has supported patient access to RNAi therapeutics amidst the ongoing global pandemic.
Our team has always understood that the science of RNAi therapeutics was step one. The ultimate challenge would be ensuring our patients globally have access to our therapies, independent of their financial status and external events. I very proud of the progress we've made, reflected in this report, and believe that we're transforming the way patient access is conceived and approached globally. – John Maraganore, PhD, Alnylam CEO
Highlights of the 2021 Patient Access Philosophy Report include:
Supporting patients from clinical development of new therapies through commercialization: Around the world, more than 2,250 commercial patients managing rare diseases now rely on Alnylam’s therapies. Alnylam’s global programs and partnerships inform and empower patients to get access to education and care, guided by the belief that no patient should have to wait for hope. Through these partnerships, Alnylam has:
Collaborating with more partners worldwide to define value and support access: Alnylam’s growth in new markets is accompanied by extensive collaboration around value-based care and responsible pricing. By working with local governments, private and public payers, and distribution partners, Alnylam continues to produce innovative solutions that remove barriers to care, globally. Through these partnerships, Alnylam has:
We hope that you will take the time to read the 2021 Patient Access Philosophy Report and learn how we are doing our part to improve access worldwide.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site